These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 11488735)
21. The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis. Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS Br J Urol; 1997 Feb; 79(2):217-20. PubMed ID: 9052473 [TBL] [Abstract][Full Text] [Related]
22. Biochemical markers for assessment of bone metastases in patients with breast cancer. Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361 [TBL] [Abstract][Full Text] [Related]
23. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis. Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250 [TBL] [Abstract][Full Text] [Related]
24. Usefulness of bone markers for detection of bone metastases in lung cancer patients. Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691 [TBL] [Abstract][Full Text] [Related]
25. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]. Taue R; Kanayama H; Kagawa S Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358 [TBL] [Abstract][Full Text] [Related]
26. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study. Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337 [TBL] [Abstract][Full Text] [Related]
27. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Ikeda I; Miura T; Kondo I Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer. Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655 [TBL] [Abstract][Full Text] [Related]
29. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651 [TBL] [Abstract][Full Text] [Related]
30. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. Gillatt D; Reynard JM Br J Urol; 1995 Mar; 75(3):341-6. PubMed ID: 7537603 [TBL] [Abstract][Full Text] [Related]
31. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Wolff JM; Ittel T; Boeckmann W; Reinike T; Habib FK; Jakse G Eur Urol; 1996; 30(3):302-6. PubMed ID: 8931961 [TBL] [Abstract][Full Text] [Related]
33. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. Li C; Zang T; Wrobel K; Huang JT; Nabi G Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369 [TBL] [Abstract][Full Text] [Related]
34. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680 [TBL] [Abstract][Full Text] [Related]
35. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer]. Takeuchi S; Saitoh H Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511 [TBL] [Abstract][Full Text] [Related]
36. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Ebert W; Muley T; Herb KP; Schmidt-Gayk H Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610 [TBL] [Abstract][Full Text] [Related]
37. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate. Wolff JM; Ittel T; Borchers H; Brauers A; Jakse G Urol Int; 1998 Oct; 61(1):12-6. PubMed ID: 9792976 [TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571 [TBL] [Abstract][Full Text] [Related]
40. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]